HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sacktor, N. Articles by Kieburtz, K. Search for Related Content PubMed PubMed Citation Articles by Sacktor, N. Articles by Kieburtz, K.

Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study

From the Department of Neurology (Drs. Sacktor and McArthur), Johns Hopkins University School of Medicine, Baltimore, MD; Departments of Neurology (Drs. Schifitto and Kieburtz) and Biostatistics (Dr. McDermott), University of Rochester Medical Center, Rochester, NY; and Department of Neurology (Dr. Marder), Columbia University, New York, NY.

Address correspondence and reprint requests to Dr. Ned Sacktor, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Department of Neurology, 4940 Eastern Avenue, B-building, Room 122, Baltimore, MD 21224; e-mail: sacktor{at}jhmi.edu

The authors conducted a pilot randomized, double-blind, placebo-controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.

Key words: Selegiline—HIV—Cognitive impairment

This article has been cited by other articles:

				G. Schifitto, J. Zhang, S. R. Evans, N. Sacktor, D. Simpson, L. L. Millar, V. L. Hung, E. N. Miller, E. Smith, R. J. Ellis, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment Neurology, September 25, 2007; 69(13): 1314 - 1321. [Abstract] [Full Text] [PDF]

				M. C. Zink, J. Uhrlaub, J. DeWitt, T. Voelker, B. Bullock, J. Mankowski, P. Tarwater, J. Clements, and S. Barber Neuroprotective and Anti-Human Immunodeficiency Virus Activity of Minocycline JAMA, April 27, 2005; 293(16): 2003 - 2011. [Abstract] [Full Text] [PDF]

				M. R. Watters, P. W. Poff, B. T. Shiramizu, P. S. Holck, K. M.S. Fast, C. M. Shikuma, and V. G. Valcour Symptomatic distal sensory polyneuropathy in HIV after age 50 Neurology, April 27, 2004; 62(8): 1378 - 1383. [Abstract] [Full Text] [PDF]

				K. Marder, S. M. Albert, M. P. McDermott, J. C. McArthur, G. Schifitto, O. A. Selnes, N. Sacktor, Y. Stern, D. Palumbo, K. Kieburtz, et al. Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment Neurology, May 13, 2003; 60(9): 1467 - 1473. [Abstract] [Full Text] [PDF]

				J. Turchan, C.B. Pocernich, C. Gairola, A. Chauhan, G. Schifitto, D.A. Butterfield, S. Buch, O. Narayan, A. Sinai, J. Geiger, et al. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants Neurology, January 28, 2003; 60(2): 307 - 314. [Abstract] [Full Text] [PDF]